Workshop A Tuesday, May 07
9:00 am - 12:00 am
Effective Scale-Up to Achieve Commercialization of Allogeneic Cell Therapies
CSO , CytoSen Therapeutics
Robert Igarashi, CSO , CytoSen Therapeutics
Robert Igarashi, Ph.D. is the president and co-founder of CytoSen Therapeutics. Dr. Igarashi has a diverse background in life sciences and has played an instrumental role in the development of the particle based natural killer (NK) cell stimulating technology. He has brought his biochemical and physico-chemical expertise to combine with immunology for developing and refining the nanoparticle based method for NK cell stimulation that could be used for ex vivo expansion as well as in vivo stimulation of therapeutic NK cells.He has been crucial in understanding the biochemical aspects of the plasma membrane particles interacting with NK cells and how they can be further innovated to add novel therapeutic dimensions for adoptive NK cell therapy.
Workshop B Tuesday, May 07
1:00 pm - 4:00 pm
Building Your Own GMP Infrastructure for CAR-T – Commercial, Clinical and Regulatory Considerations
CEO , TCBiopharm
TC BioPharm (TCB) has elected to bring cell and lentiviral vector (LVV) manufacture in-house to guarantee supply of materials for our CAR-T programmes. This decision has been taken primarily to address key concerns facing our future business in the CAR-T space. This is because there continues to be limited availability of GMP-grade LVV from CDMO’s. Subcontractor bottlenecks can lead to significant delay in the manufacturing process and clinical timelines. There also is a high cost with regard LVV manufacturing (this has increased significantly with ongoing interest in CAR-T sector).
Aims of the workshop:
• To address some key considerations facing CAR-T manufacture with regard to γδ T cells
• Gain insight into de-risking strategies for developing allogeneic treatment platforms
• In-house vs contracted manufacture
• Regulatory considerations
• Shipment, starting material & end product, validation, shelf-life
• Facility design – MHRA review
• QA systems
• Platform considerations
• Release tests
• Facility design
• Cell banking – autologous vs allogeneic
• Donor recruitment
• Storage and contingency
• Media optimisation
• Release tests (auto/allogeneic)
Michael Leek, CEO , TCBiopharm
Recently presented the ‘Scottish Life-Sciences Entrepreneurial Business Leadership’ award, Michael is CEO of TC BioPharm, developing clinical-stage allogeneic CAR-T immunotherapies.
Active in the cell therapy sector for 30 years, Michael has developed ten different cell-based products to clinic including the world’s first allogeneic cell therapy to undergo multi-national (EU, US, Canada) phase 3 evaluation when he was previously responsible for moving Intercytex from a pre-clinical startup, to an AIM-listed company.
Angela Scott, COO, TCBiopharm
Angela has 32 years in oncology research and regenerative medicine, was part of the team that cloned ‘Dolly the Sheep’, and has designed, built and commissioned several GMP manufacturing facilities. She manufactured product for the UK’s ‘first-in-man’ stem cell trial (PISCES – ReNeuron), and has held MHRA -MIA and -IMP licenses for several cell therapy products.